Immunogenicity and safety of two doses of SARS-CoV-2 mRNA vaccine in kidney transplant recipients with low-dose rituximab.

Satoshi TakaiHayato NishidaHiromi ItoHiroki FukuharaTakaaki NawanoTakafumi NarisawaHidenori KannoMayu YagiAtsushi YamagishiToshihiko SakuraiSei NaitoTomoyuki KatoKeita MorikaneNorihiko Tsuchiya

Published in: International journal of urology : official journal of the Japanese Urological Association (2022)

Low-dose rituximab in kidney transplant recipients did not affect humoral or cellular responses to the severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccine without severe systemic adverse events including the deterioration of kidney function.

Keyphrases

respiratory syndrome coronavirus
low dose
sars cov
diffuse large b cell lymphoma
high dose
coronavirus disease
immune response
hodgkin lymphoma
chronic lymphocytic leukemia
early onset
binding protein
drug induced